Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bates Website

Susan Bates, M.D.

Selected Publications

1)  Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, Stein W, Robey RW, Bangiolo L, Levens D, Bates SE.
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Mol Oncol. [Epub ahead of print], 2014.
2)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. 121: 4115-25, 2013.
3)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
4)  Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey RW, Hegde RS, Bates SE.
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
Cancer Res. 72: 3642-51, 2012.
5)  Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood. 117:: 5827-34, 2011.
6)  Fojo AT, Bates SE.
Clinical trial results: a clinical trial bazaar!.
Oncologist. 19: 313-4, 2014.
7)  Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T.
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
PLoS ONE. 9: e96316, 2014.
8)  Rubin EH, Allen JD, Nowak JA, Bates SE.
Developing precision medicine in a global world.
Clin. Cancer Res. 20: 1419-27, 2014.
9)  Bates SE.
It"s All About the Test: The Complexity of Companion Diagnostic Co-development in Personalized Medicine.
Clin. Cancer Res. 20: 1418, 2014.
10)  Zhang H, Kathawala RJ, Wang Y, Zhang Y, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Ambudkar SV, Bates SE, Fu L, Chen Z.
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Int. J. Biochem. Cell Biol. 51: 111-9, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 6/30/2014.